Specific set of microRNAs could help diagnose and monitor IH treatment

NewsGuard 100/100 Score

Infantile hemangiomas (IH) are benign vascular tumors occurring in 4-5% of infants. These tumors resolve spontaneously or in response to propranolol treatment; however, they resemble other vascular anomalies and cannot be definitively diagnosed without biopsy.

In this issue of JCI Insight, Jonathan Perkins of University of Washington and colleagues analyzed IH tumor tissue, IH patient plasma, and non-IH vascular anomalies to identify a set of microRNAs that are specific for IH. MicroRNAs are small RNA molecules that do not encode genes, but instead regulate the expression of other genes. The IH-specific set of microRNAs, known as C19MC, was specifically upregulated in IH tumor cells and was also detectable in IH patient plasma. Importantly, circulating C19MC microRNAs decreased in parallel with IH tumor regression, but rebounded with tumor re-growth. These results suggest that plasma C19MC microRNAs could be used to diagnose and monitor IH treatment. Additionally, C19MC microRNAs may be important in IH pathogenesis, as their known targets include genes encoding inhibitors of cell growth and proliferation.

Source: JCI Journals


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas